drugset / Trial / NCT06816771
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.
Timeline
- Start
- 2025-02
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Ifosfamide | Small molecule | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |
| Subject | Pazopanib | Small molecule | — | Oral |
| Subject | Vinorelbine | Small molecule | — | — |